StockNews.com Initiates Coverage on Regulus Therapeutics (NASDAQ:RGLS)

Research analysts at StockNews.com assumed coverage on shares of Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) in a research report issued to clients and investors on Saturday. The firm set a "sell" rating on the biopharmaceutical company's stock.

A number of other research analysts also recently weighed in on the company. Leerink Partners restated a "market perform" rating and issued a $7.00 price target on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Jones Trading reaffirmed a "hold" rating and set a $7.00 price target (down from $8.00) on shares of Regulus Therapeutics in a research report on Wednesday, April 30th. Wells Fargo & Company reissued an "equal weight" rating and issued a $9.00 price objective on shares of Regulus Therapeutics in a research report on Thursday, May 1st. Canaccord Genuity Group reaffirmed a "hold" rating and issued a $11.00 target price (down from $28.00) on shares of Regulus Therapeutics in a report on Wednesday, April 30th. Finally, Leerink Partnrs downgraded shares of Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, Regulus Therapeutics presently has an average rating of "Hold" and a consensus price target of $8.50.

Regulus Therapeutics Price Performance

Shares of RGLS stock remained flat at $7.87 during trading hours on Friday. The stock had a trading volume of 1,014,368 shares, compared to its average volume of 879,969. The company has a market capitalization of $521.33 million, a PE ratio of -7.36 and a beta of 0.49. The business's fifty day simple moving average is $2.76 and its two-hundred day simple moving average is $1.88. Regulus Therapeutics has a one year low of $0.83 and a one year high of $8.20.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.14. Equities research analysts forecast that Regulus Therapeutics will post -0.88 earnings per share for the current fiscal year.

Institutional Trading of Regulus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC purchased a new stake in Regulus Therapeutics in the third quarter worth $46,000. Barclays PLC grew its position in shares of Regulus Therapeutics by 285.2% during the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company's stock valued at $132,000 after purchasing an additional 62,549 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Regulus Therapeutics by 193.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company's stock valued at $124,000 after acquiring an additional 52,059 shares in the last quarter. Renaissance Technologies LLC lifted its position in Regulus Therapeutics by 20.5% during the fourth quarter. Renaissance Technologies LLC now owns 117,100 shares of the biopharmaceutical company's stock valued at $185,000 after purchasing an additional 19,900 shares during the last quarter. Finally, PEAK6 LLC bought a new stake in Regulus Therapeutics during the fourth quarter worth about $95,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.